Modified Docetaxel and Cisplatin in Combination with Capecitabine (DCX) as a First-Line Treatment in HER2-Negative Advanced Gastric Cancer

Bılıcı, Ahmet; Selçukbiricik, Fatih; Demir, Nazan; Ustaalioğlu, Bala Basak Oven; Dikilitaş, Mustafa; Yıldız, Özcan

doi:10.7314/apjcp.2014.15.20.8661

Cited by 8 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Real-2 multicenter clinical trial found that 5-FU infusion and capecitabine had similar effectiveness. 29 This substitution not only reduced the hematological toxicity as previously reported, 27,37,38 but also eliminated the requirement for hospitalization, as a central venous access device was no longer required. As expected, the ORR in our study were comparable to those of the DCF and its modification regimens (42.1% vs 25%-48.7%) 9,14,[39][40][41][42] while the toxicity profile was more favorable.…”

mentioning

confidence: 59%

“… 5 DCX (docetaxel, cisplatin and capecitabine), a modified regimen of DCF, had varied incidence of severe neutropenia and febrile neutropenia across studies (16–62% for severe neutropenia and 4.5–19% for febrile neutropenia). 37 , 38 , 60 Substituting docetaxel with paclitaxel, as well as the introduction of oral capecitabine as an alternative to intravenous 5-FU, may play a role in alleviating hematological toxicity, as shown in previous studies. 16–18 , 37 , 38 , 60 …”

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 85%

“…37,38,60 Substituting docetaxel with paclitaxel, as well as the introduction of oral capecitabine as an alternative to intravenous 5-FU, may play a role in alleviating hematological toxicity, as shown in previous studies. [16][17][18]37,38,60 To our knowledge, this is the first prospective cohort study evaluating the efficacy and toxicity of TCX regimen in patients with advanced stage cancer. The relatively small sample size, short follow-up period, and lack of a control group were the main disadvantages of this study.…”

mentioning

confidence: 82%

See 3 more Smart Citations

Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study

Nguyen¹,

Hung²,

Le³

et al. 2022

CMAR

View full text Add to dashboard Cite

Objective To evaluate the outcome and safety of the paclitaxel, carboplatin, and capecitabine (TCX) regimen in patients with advanced gastric cancer. Methods Advanced gastric cancer patients received the TCX regimen for up to six cycles, which were 3 weeks apart. Paclitaxel (175 mg/m2) was given over a 3-hour infusion, followed by carboplatin in a 1-hour infusion on day 1. Capecitabine (850 mg/m2) was given orally twice daily from day 1 to day 14. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Results Among 83 patients at stage IVa and IVb, the median PFS was 9.3 months; 6-month, 1-year, and 2-year PFS were 74.6%, 32.5%, and 14.4%, respectively. The median OS was 17.0 months; 6-month, 1-year, and 2-year OS were 97.5%, 68.7%, and 21.7%, respectively. In the multivariable Cox regression model, higher CEA was associated with poor OS. Common adverse events included hand-food syndrome (77.9%), peripheral neuropathy (63.2%), fatigue (68.7%), and nausea (54.2%). Conclusion The TCX regimen provided good survival and a better safety profile. More clinical trials are needed to confirm its treatment efficacy and safety, especially in comparison with other triplet regimens.

show abstract

mentioning

confidence: 59%

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 85%

mentioning

confidence: 82%

See 2 more Smart Citations

Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study

Nguyen¹,

Hung²,

Le³

et al. 2022

CMAR

View full text Add to dashboard Cite

show abstract

Kurarinone Synergizes TRAIL-Induced Apoptosis in Gastric Cancer Cells

Zhou

Wang

et al. 2014

Cell Biochem Biophys

View full text Add to dashboard Cite

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been identified as a promising anti-tumor agent against in a variety of cancers. However, gastric cancer cells are less sensitive than other cancer cells to TRAIL-induced apoptosis. Here, we combined TRAIL with kurarinone, a natural compound, to induce apoptosis in gastric cancer cell lines SGC7901. After the cells were treated with TRAIL and/or kurarinone, the cell viability and apoptosis were examined by MTT and flow cytometry, respectively. The expression of apoptosis-associated proteins was determined by western blot and q-RT-PCR. Kurarinone at low concentration significantly potentiated the cytotoxic effect of TRAIL by enhancing apoptosis as well as cell cycle arrest at G2/Mphase. The enhancement of apoptosis TRAIL induced by kurarinone involved downregulation of anti-apoptotic proteins Mcl-1 and c-FLIP as well as inhibition of STAT3 signaling. Moreover, we found that STAT3 inhibitor could synergistically enhanced TRAIL-induced apoptosis, similar to kurarinone. Kurarinone synergizes TRAIL-induced apoptosis in human gastric cancer cells. The synergistic effect between these two drugs is associated with downregulation of Mcl-1 and c-FLIP via inhibiting STAT3 signaling. The combination of TRAIL and kurarinone might be an effective regimen for the treatment of advanced gastric cancer.

show abstract

A Prospective Phase I/II Study of Docetaxel, Cisplatin and Continuous Capecitabine in Advanced Oesophago-Gastric Cancer (NWCOG-3)

et al. 2018

View full text Add to dashboard Cite

Modified Docetaxel and Cisplatin in Combination with Capecitabine (DCX) as a First-Line Treatment in HER2-Negative Advanced Gastric Cancer

Cited by 8 publications

References 25 publications

Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study

Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study

Kurarinone Synergizes TRAIL-Induced Apoptosis in Gastric Cancer Cells

A Prospective Phase I/II Study of Docetaxel, Cisplatin and Continuous Capecitabine in Advanced Oesophago-Gastric Cancer (NWCOG-3)

Contact Info

Product

Resources

About